Large language models (LLMs) have transformative potential in radiology, including textual summaries, diagnostic decision support, proofreading, and image analysis. However, the rapid increase in studies investigating these models, along with the lack of standardized LLM-specific reporting practices, affects reproducibility, reliability, and clinical applicability. To address this, reporting guidelines for LLM studies in radiology were developed using a two-step process. First, a systematic review of LLM studies in radiology was conducted across PubMed, IEEE Xplore, and the ACM Digital Library, covering publications between May 2023 and March 2024. Of 511 screened studies, 57 were included to identify relevant aspects for the guidelines. Then, in a Delphi process, 20 international experts developed the final list of items for inclusion. Items consented as relevant were summarized into a structured checklist containing 32 items across six key categories: general information and data input; prompting and fine-tuning; performance metrics; ethics and data transparency; implementation, risks, and limitations; and further/optional aspects. The final FLAIR (Framework for LLM Assessment in Radiology) checklist aims to standardize reporting of LLM studies in radiology, fostering transparency, reproducibility, comparability, and clinical applicability to enhance clinical translation and patient care. © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license. Supplemental material is available for this article.
Introduction Ritlecitinib, an oral, selective JAK3/TEC family kinase inhibitor, demonstrated efficacy and safety up to 48 weeks in patients aged ≥12 years with alopecia areata (AA) in the ALLEGRO phase 2b/3 study (NCT03732807). This updated integrated safety analysis evaluated the safety of ritlecitinib up to ~5 years in patients with AA in two phase 2a studies (NCT04517864; NCT02974868), the phase 2b/3 study, and an ongoing long-term, phase 3, open-label study (NCT04006457) from the ALLEGRO program. Methods Safety data were pooled from the 4 studies. Proportions and incidence rates (IRs; IR/100 patient-years [PYs]) of adverse events (AEs) are reported for the any-ritlecitinib (any dose) and ritlecitinib 50-mg ± 200-mg (50 mg ± 4-week 200-mg loading dose) groups. These analysis groups are not additive and are overlapping populations, with the any-ritlecitinib group including all patients. Results In the any-ritlecitinib (n=1294) and 50-mg ± 200-mg (n=1228) groups, median duration of exposure was 1204 (3539.5 PYs) and 1197 (3261.5 PYs) days, respectively. AEs occurred in 1158 (89.5%; 167.9/100 PYs) and 1070 (87.1%; 148.1/100 PYs) patients in the any-ritlecitinib and 50-mg ± 200-mg groups, respectively. The most common AEs included headache, positive SARS-CoV-2 test, and nasopharyngitis. Serious AEs occurred in 88 (6.8%; 2.5/100 PYs) patients in the any-ritlecitinib group and 84 (6.8%; 2.6/100 PYs) patients in the 50-mg ± 200-mg group, and included 2 deaths (breast cancer and acute respiratory failure/cardiorespiratory arrest) in the 50-mg ± 200-mg group. Discontinuations due to AEs occurred in 7.0% and 6.6% in the any-ritlecitinib and 50-mg ± 200-mg groups, respectively. IRs for both groups were 0.1/100 PYs for opportunistic infections; 1.0/100 PYs for herpes zoster; 0.3/100 PYs for malignancies, excluding nonmelanoma skin cancer; and 0.2/100 PYs for major adverse cardiovascular events. Conclusion Ritlecitinib was generally well tolerated ~5 years in patients with AA. Safety was consistent with previously reported data. Funding This study was funded by Pfizer Inc.
RATIONALE:Efficient distribution of scarce critical care resources is essential to save the most lives in times of crisis. Evidence-based practices and processes enhance clinical decision-making. OBJECTIVES:The objective of these guidelines was to develop evidence-based, rather than expert-based, recommendations for triaging critically ill patients eligible for ICU admission during times of crisis-level shortages in ICU capacity. DESIGN:The American College of Critical Care Medicine Board convened a 21-member multidisciplinary panel, comprising doctors in medicine, nursing, and law; advanced practice providers; respiratory therapists; ethicists; and patient/family representatives. The panel included two expert methodologists specialized in developing evidence-based recommendations in alignment with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Conflict-of-interest policies were strictly followed during all phases of guidelines development including task force selection and voting. METHODS:The panel members identified and formulated five fundamental Patient, Intervention, Comparator, and Outcomes questions. The panel conducted a systematic review for each question to identify the best available evidence, analyzed the evidence, and assessed the certainty of the evidence using the GRADE methodology. The GRADE evidence-to-decision framework was used to formulate the recommendations. Good practice statements were included to provide additional guidance. RESULTS:The panel generated one conditional recommendation and five no recommendation statements. CONCLUSIONS:Crisis-level shortages significantly disrupt patient care. Despite the role of triage in minimizing adverse outcomes, there is a lack of evidence, as opposed to expert opinion, to guide practice recommendations in the critical clinical scenarios considered by the panel.
BACKGROUND:Janus kinase inhibitors (JAKis) have transformed the treatment of alopecia areata (AA), but not all patients respond to initial therapy. The utility of switching between JAKis in treatment-refractory AA remains underexplored. OBJECTIVE:To evaluate the efficacy and safety of switching between JAKis in patients with severe AA. METHODS:In this multicenter retrospective study, we analyzed 108 patients with severe AA who switched between oral JAKis after a minimum treatment duration of 6 months. Treatment response was assessed using the Severity of Alopecia Tool (SALT). Multivariable logistic regression was used to identify predictors of response to a second JAKi. RESULTS:Overall, 48.8% of patients achieved SALT ≤20 on their second JAKi, and 32.6% achieved SALT ≤10. Of 21 patients who received a third JAKi, 52.4% achieved SALT ≤20 and 38.1% achieved SALT ≤10. Patients who responded to their first JAKi were more likely to respond to a second (odds ratio, 3.33; 95% CI, 1.22-9.68; P = .022). Adverse events were mild and consistent with prior reports. LIMITATIONS:Retrospective design, treatment heterogeneity, and potential selection bias. CONCLUSIONS:Switching between JAKis appears to be a viable strategy for severe AA patients, especially those responding to prior JAKi. Prior response may help guide treatment sequencing.
OBJECTIVES:The EARLY TAVR trial demonstrated improved clinical outcomes for patients with asymptomatic severe aortic stenosis (aSAS) treated with transcatheter aortic valve replacement (eTAVR) compared with clinical surveillance (CS). The cost-effectiveness of an eTAVR strategy for patients with aSAS in the United States is unknown. METHODS:A Markov model with 30-day cycles was developed from the US healthcare payor perspective to estimate the cost-effectiveness of eTAVR vs CS over a lifetime horizon. Inputs for population characteristics and health outcomes were derived from the EARLY TAVR trial. Costs were derived from US Medicare reimbursement rates. Probabilistic and deterministic sensitivity analyses were performed to evaluate the effect of parameter uncertainty on model output. RESULTS:When compared with CS, eTAVR was associated with 0.21 additional life-years (LY) and 0.24 additional quality-adjusted life-years over a lifetime because of more time spent in the alive and well health state with eTAVR. Lifetime costs were estimated to be $8812 lower, due primarily to reductions in costs associated with the AVR procedure, stroke, and heart failure hospitalizations. Accordingly, eTAVR was projected to be economically dominant over CS. In probabilistic sensitivity analysis, a large majority of iterations (95.9%) produced cost-effective results ($100 000 threshold) for eTAVR versus CS, with most simulations (90.3%) showing dominance, confirming the robustness of the base-case results. These findings were consistent over a variety of scenario analyses. CONCLUSIONS:An eTAVR strategy for the treatment of aSAS may be a cost-saving approach for US healthcare payors, when compared with CS.